Physician profile
Amanda Thore
NPI 1659856656
$6,123.31
in general payments reported to CMS, 2019-2025
39 companies · $985 in 2025
The $985 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,337 · 2022: $1,530 · 2023: $1,068 · 2024: $1,203 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,241 · Education: $15.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,240.86 |
| Education | $15.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,198.06 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $904.41 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $529.53 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $404.59 | 2021-2024 | |
| Pfizer INC. | $359.06 | 2021-2025 | |
| Lilly USA, LLC | $302.30 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $291.58 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.07 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Otsuka America Pharmaceutical, INC. | $228.24 | 2022-2025 | Rexulti |
| Amgen INC. | $143.94 | 2021-2024 | Otezla, Repatha, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.55 | 2021-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $112.34 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $107.51 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.45 | 2022-2024 | |
| Amarin Pharma, INC. | $94.85 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Thore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.